Welcome to our dedicated page for Scynexis SEC filings (Ticker: SCYX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SCYNEXIS, Inc. (SCYX) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on SCYNEXIS’s antifungal drug development programs, its exclusive license agreement with GSK for ibrexafungerp and BREXAFEMME, financial condition, governance, and risk factors.
Investors can review annual reports on Form 10-K and quarterly reports on Form 10-Q for comprehensive discussions of the company’s fungerp platform, including ibrexafungerp and second-generation candidate SCY-247, as well as descriptions of clinical programs, collaboration terms, and revenue recognition from the GSK license agreement. These periodic reports also summarize research and development expenses, selling, general and administrative costs, cash balances, and other key financial metrics.
Current reports on Form 8-K capture material events such as the binding memorandum of understanding with GSK resolving the disagreement over the Phase 3 MARIO study, associated payments, and updates on the transfer of the BREXAFEMME New Drug Application. Other 8-K filings describe Nasdaq listing notices, annual meeting voting results, and similar corporate developments.
This page also surfaces proxy statements and related materials that address director elections, advisory votes on executive compensation, and auditor ratification. Together, these documents help users understand SCYNEXIS’s governance structure and shareholder decisions.
Stock Titan enhances these filings with AI-powered summaries that explain complex sections in plain language, highlight key changes from prior periods, and point out items such as license agreement terms, clinical program disclosures, and capital structure details. Users can quickly scan new 10-K, 10-Q, and 8-K filings, as well as track warrant liabilities, deferred revenue, and other line items that SCYNEXIS reports in its financial statements.
Federated Hermes, Inc. and related Reporting Persons report beneficial ownership of 5,116,598 shares of Scynexis Inc. common stock, representing 11.26% of the outstanding shares as of the event date 09/30/2025. The filing is an Amendment to Schedule 13G and lists ownership held by Federated Hermes, Inc., Voting Shares Irrevocable Trust, and three individual reporting persons who share voting and dispositive power over the same block. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. Signatures for the filing and trust acknowledgments are dated 10/07/2025, with exhibits noted for subsidiary classification, a joint filing agreement, and a power of attorney.
SCYNEXIS, Inc. reported that the FDA lifted the clinical hold on ibrexafungerp on April 24, 2025, and dosing in the Phase 3 MARIO study resumed in May 2025, prompting the company to bill a $10.0 million development milestone to GSK in Q2 2025. The company is disputing GSK’s April 28, 2025 notice that purported to terminate the MARIO study and deny further milestone payments, including a $30.0 million milestone tied to study resumption.
Financially, SCYNEXIS recognized $1.364 million in license revenue for the quarter and reported a net loss of $6.885 million for Q2 2025 ($12.276 million year-to-date). Cash and investments totaled $46.5 million at June 30, 2025 (down from $75.1 million at year-end), the March 2019 convertible notes were repaid $14.0 million in March 2025, and the accumulated deficit was $388.8 million. The company received a Nasdaq deficiency notice on June 20, 2025 for a closing bid below $1.00 and has until December 17, 2025 to regain compliance. Ongoing securities class and derivative lawsuits remain pending.
SCYNEXIS (Nasdaq: SCYX) disclosed receipt of a Nasdaq bid-price deficiency notice on 20 Jun 2025 after its shares closed below $1.00 for 30 straight sessions.
The company has 180 days (until 17 Dec 2025) to lift the bid to at least $1 for 10 consecutive trading days. If unsuccessful, it may transfer to the Nasdaq Capital Market for another 180-day cure or face delisting, subject to appeal.
- Current Nasdaq Global Market listing remains unaffected.
- Management can pursue a reverse stock split or other actions to regain compliance.
- The notice heightens liquidity and funding risk and could deter institutional holders.